NASDAQ OMX

Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates

Dela

WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2017.

"We recently had a meeting with the U.S. Food and Drug Administration (FDA) to obtain feedback and guidance related to the Phase III clinical development of MIN-101 as a treatment for negative symptoms of schizophrenia," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "We expect to initiate Phase III development of this compound in the second half of 2017."

Clinical Development Updates

MIN-101:

  • An "end-of-Phase II meeting" with the FDA took place recently to review pre-clinical and clinical data generated to date with MIN-101 and to discuss Phase III and Phase IV clinical development of this compound to treat negative symptoms in patients with a diagnosis of schizophrenia, including pivotal trial design.    

MIN-117:

  • Following the acceptance of the Investigational New Drug application (IND) for MIN-117 by the FDA late last year, Minerva is planning clinical trials with this compound in the U.S. and Europe.  These trials will build upon the results from the Phase IIa trial with MIN-117, and they are expected to begin in late 2017.

MIN-202 (JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • The planned indications for the next stage of clinical development with MIN-202 include insomnia without neuro-psychiatric comorbid symptoms and comorbid insomnia in patients suffering from depressive disorders.  A number of supportive activities and clinical pharmacology studies are being conducted by Minerva and Janssen in preparation for trials in both indications.

First Quarter 2017 Financial Results

  • Net Loss:  Net loss was $10.6 million for the first quarter of 2017, or a loss per share of $0.30 (basic and diluted), compared to a net loss of $8.0 million, or a loss per share of $0.29 (basic and diluted) for the first quarter of 2016.
     
  • R&D Expenses: Research and development (R&D) expenses were $7.6 million in the first quarter of 2017, compared to $5.4 million in the first quarter of 2016.  R&D expense in the three month periods ended March 31, 2017 and 2016 included non-cash stock based compensation expenses of $0.5 million and $0.2 million, respectively.  This increase in R&D expenses primarily reflects higher development expenses under the MIN-202 program for Phase II clinical trial preparation and an increase in non-cash, stock-based compensation expenses.  These amounts were partially offset by lower costs due to the completion of our Phase IIb clinical trial of MIN-101 and the completion of our Phase IIa clinical trial of MIN-117. 
     
  • G&A Expenses: General and administrative (G&A) expenses were $2.9 million in the first quarter of 2017, compared to $2.4 million in the first quarter of 2016.  G&A expense in the three month periods ended March 31, 2017 and 2016 included non-cash stock-based compensation expenses of $0.8 million and $0.6 million, respectively. This increase in general and administrative expenses was primarily due to an increase in legal and professional fees, an increase in non-cash stock-based compensation expenses, and increased personnel costs during the three months ended March 31, 2017.
     
  • Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2017 were approximately $85.4 million.  The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 2971783.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones with MIN-101, MIN-202 and MIN-117, including the planned Phase III trial of MIN-101, the timing and scope of future clinical trials and results of clinical trials with these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether any of our therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of any of our therapeutic products, if any, will be consistent with the results of past clinical trials; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 4, 2017.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.



CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
  March 31, December 31,
  2017     2016  
  (in thousands)
ASSETS
Current Assets:    
Cash and cash equivalents $   68,895   $   82,981  
Marketable securities     16,465       -   
Restricted cash     80       80  
Prepaid expenses and other current assets     792        803  
Total current assets     86,232       83,864  
Equipment, net     6       10  
In-process research and development     34,200       34,200  
Goodwill     14,869       14,869  
Total Assets $   135,307   $   132,943  
     
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:    
Notes payable - current portion $   4,959   $   4,854  
Accounts payable     3,276       1,467  
Accrued expenses and other current liabilities     1,673       816  
             
Accrued collaborative expenses     3,078       2,548  
             
Total current liabilities     12,986       9,685  
     
Long-Term Liabilities:    
Notes payable - noncurrent     2,601       3,841  
Deferred taxes      13,434       13,434  
Total liabilities     29,021       26,960  
Stockholders' Equity:    
Common stock     4       4  
Additional paid-in capital     249,785       238,837  
Accumulated deficit     (143,503 )     (132,858 )
Total stockholders' equity     106,286       105,983  
Total Liabilities and Stockholders' Equity $   135,307   $   132,943  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)      
    Three Months Ended March 31,
     
    (in thousands, except per share amounts)
      2017     2016  
       
Revenues   $   -    $   -   
Operating expenses:      
Research and development       7,614       5,375  
General and administrative       2,871       2,382  
Total operating expenses       10,485       7,757  
       
Foreign exchange losses       (17 )     (9 )
Investment income       59       32  
Interest expense       (202 )     (270 )
Net loss   $   (10,645 ) $   (8,004 )
Loss per share:      
Basic and diluted   $   (0.30 ) $   (0.29 )
Weighted average shares:      
Basic and diluted       35,370       27,203  

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Senegal and France to host Global Partnership for Education Financing Conference20.9.2017 23:00Pressmeddelande

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- The Global Partnership for Education (GPE) is delighted that the governments of Senegal and France will co-host its financing conference, which will take place on February 8, 2018 in Dakar, Senegal. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d3003cff-ee20-409f-9729-9a9cef1d4d3e A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0a7eebb6-66b3-438b-904e-efeff83d94cf The announcement of the co-hosting was made by Presidents Macky Sall of Senegal and Emmanuel Macron of France at a high-level event on education financing held at the United Nations, which was attended by Secretary General António Guterres, several heads of state and leaders on global education. " The Global Partnership for Education has   made substantial investments in education helpin

K2 Launches New Process Automation Platform Including New Cloud Service20.9.2017 18:00Pressmeddelande

K2's process automation platform allows businesses of all types around the globe to rapidly build and deploy automation across the business. BELLEVUE, Wash., Sept. 20, 2017 (GLOBE NEWSWIRE) -- K2 today announced the availability of its new low-code process automation platform - furthering innovation in the way organizations drive digital efficiencies. With a new managed cloud service, K2 Cloud, new on-premises version, K2 Five, and completely redesigned user interfaces and experiences, the platform helps businesses of all types around the globe rapidly deliver powerful process automation and realize business productivity gains. Automating business processes across an enterprise is crucial to the success of companies in the era of digital transformation. However, many initiatives are impacted by a lack of sufficient resources and the use of inefficient systems to manage processes. K2's low-code process automation platform solves these problems by enabling organ

8x8 and Aryaka Partner to Enhance Cloud Communications for Global Enterprises20.9.2017 16:43Pressmeddelande

Strategic Alliance will improve communications experience for business users worldwide SAN MATEO, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, and 8x8, Inc. (NASDAQ:EGHT), the world's first Communications Cloud provider, today announced that they are entering a strategic partnership that will improve the performance and reliability of business-critical cloud unified communications. This will enable global mid-market and enterprise companies to enhance business communications, collaboration and customer engagement for their employees, customers and partners around the world. Through this partnership, Aryaka's global SD-WAN solution will provide enterprise-grade private connectivity to further enhance the superior voice and video quality delivered by the 8x8 Communications Cloud(TM). When tested against several leading Unified Communications as a Service (UCaaS) providers, 8x8 was recently found by the Tolly Group to deliver the hi

NRT Technology Corp and Gaming Payments Innovator Sightline Payments Announce Merger20.9.2017 16:00Pressmeddelande

Combination Will Accelerate Innovation in Mobile, Data, Cashless Payments, and Provisional Credit Solutions to the Worldwide Integrated Resort Casino Industry LAS VEGAS, Sept. 20, 2017 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT") a leading provider of integrated ticket redemption and payment services to global casino operators, and Sightline Payments ("Sightline"), developers of the disruptive Play+ platform that's powering the next generation of cashless and mobile gaming payment solutions, announced today an agreement to merge.  The company on closing will be named NRT Sightline and will form one of the largest pure play gaming payment technology companies in the world with an equity value of over $300 million. Following the closing of the transaction and subject to regulatory approvals, Sightline's CEO and Founder, Kirk Sanford, will assume the role of President and CEO of NRT Sightline.  NRT's current Founder, P

BT and Hitachi Partner to Develop Industrial and Enterprise IOT Solutions20.9.2017 15:00Pressmeddelande

Initial Focus on Asset Intelligence and Predictive Maintenance Use Cases LAS VEGAS and LONDON, Sept. 20, 2017 (GLOBE NEWSWIRE) -- BT, one of the world's leading providers of communications services and solutions, and Hitachi Vantara, a wholly owned subsidiary of Hitachi Ltd. (TSE:6501) today announced a global partnership to co-create innovative solutions in the area of industrial and enterprise internet of things (IoT). The partnership aims to drive better business outcomes for global customers, including greater efficiency, productivity and cost savings. The companies will initially focus on exploring and designing asset intelligence and predictive maintenance solutions to deliver the desired outcomes for customers in industry sectors such as manufacturing and transportation. Announced at Hitachi's inaugural user conference, Hitachi NEXT 2017, in Las Vegas today, the partnership unites BT's global network infrastructure, cloud capabiliti

XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer20.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status. Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 pati

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum